Cellular manufacturing of pluripotent embryonic stem cells in a NovaPod system
Lead Research Organisation:
University of Manchester
Department Name: Dentistry
Abstract
Please see application submitted directly to TSB
People |
ORCID iD |
| Christopher Ward (Principal Investigator) |
Publications
Dou R
(2015)
High throughput cryopreservation of cells by rapid freezing of sub-µl drops using inkjet printing--cryoprinting.
in Lab on a chip
Hawkins K
(2012)
E-cadherin and, in its absence, N-cadherin promotes Nanog expression in mouse embryonic stem cells via STAT3 phosphorylation.
in Stem cells (Dayton, Ohio)
Hawkins K
(2014)
Novel Cell Lines Isolated From Mouse Embryonic Stem Cells Exhibiting De Novo Methylation of the E-Cadherin Promoter
in Stem Cells
Mohamet L
(2014)
Familial Alzheimer's disease modelling using induced pluripotent stem cell technology.
in World journal of stem cells
Mohamet L
(2011)
Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.
in Journal of oncology
Segal JM
(2017)
Novel peptides for deciphering structural and signalling functions of E-cadherin in mouse embryonic stem cells.
in Scientific reports
Soncin F
(2009)
Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal.
in Stem cells (Dayton, Ohio)
Soncin F
(2011)
The function of e-cadherin in stem cell pluripotency and self-renewal.
in Genes
| Description | Various peptides for the inhibition of E-cadherin have been designed and evaluated. They allow the culture of embryonic stem cells in monolayer and suspension culture. Peptides have also allowed the investigation of pathways associated with tumour cell spread and proliferation and allow differentiation of ES cells into neuroprogenitor cells in the absence of exogenous growth factors. |
| Exploitation Route | University of Manchester spin-out company has been formed to exploit the results of this grant. |
| Sectors | Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
| URL | http://www.manchester.ac.uk/research/christopher.ward/ |
| Description | Patent awarded in Europe and USA (WO2007088372). Further patent filed in 2012 (WO2014072720). 7 peer-reviewed papers published from this grant. Spin-out company formed to exploit technology (StrataStem Ltd). |
| First Year Of Impact | 2008 |
| Sector | Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Societal Economic |
| Description | EPSRC Stem cell strategy development panel. Royal Society, London. Panel member. 16th March 2009. |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Stem cell call funded by EPSRC |
| Description | TSB Stratified Medicine strategy on neurodegenerative diseases workshop October 2013 |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Call for neurodegenerative diseases funded |
| Description | BBSRC Pathfinder award |
| Amount | £13,319 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2012 |
| End | 05/2012 |
| Description | BBSRC follow-on-fund |
| Amount | £216,979 (GBP) |
| Funding ID | BB/K020277/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2013 |
| End | 04/2015 |
| Description | Crack-It UnTangle NC3Rs |
| Amount | £81,956 (GBP) |
| Funding ID | 35529-259127 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2013 |
| End | 06/2014 |
| Description | DPUK: Integrated Dementia Research Environment |
| Amount | £6,091,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 09/2016 |
| Description | EPSRC Stem cell call |
| Amount | £2,637,207 (GBP) |
| Funding ID | EP/H046070/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2011 |
| End | 12/2014 |
| Description | IAA Concept study |
| Amount | £62,537 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 09/2015 |
| Description | Microfluidic Modulation of Embryonic Stem Cell Differentiation in Well-Defined Microscopic Flow (KTA Award 104: 2010-2011). |
| Amount | £35,243 (GBP) |
| Organisation | University of Sheffield |
| Department | EPSRC KTA Knowledge Transfer Account |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2010 |
| End | 04/2011 |
| Description | Proximity to Discovery Secondment Grant |
| Amount | £57,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 05/2016 |
| Description | UK UKDP: Integrated Dementia Research Environment |
| Amount | £2,329,271 (GBP) |
| Funding ID | MR/M009076/1 |
| Organisation | Medical Research Council (MRC) |
| Department | Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 09/2016 |
| Description | University of Manchester, The |
| Amount | £117,000 (GBP) |
| Funding ID | PoP fund |
| Organisation | University of Manchester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2012 |
| End | 09/2013 |
| Title | Differentiation of iPSCs to neural progenitor cells |
| Description | Small peptides developed during this grant has been used to derive homogeneous populations of neural progenitor cells from iPSCs (human and mouse). |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | NC3Rs Phase 1 grant award for the development of a Tau cell model |
| Title | Peptide development |
| Description | Small peptides have been developed during this grant that enable modification of gene transcript expression in embryonic stem cells |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2012 |
| Provided To Others? | Yes |
| Impact | Several papers published by me and collaborators published |
| Title | Suspension culture of ES/iPS cells |
| Description | Small peptides developed during this grant that allows the culture of iPSCs and ES cells (human and mouse) in suspension culture. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Industry collaborations with Lonza. |
| Title | Microarray analysis of E-cadherin inhibition in cells |
| Description | Microarray analysis of E-cadherin inhibition in mouse and human ES cells and mammary epithelial tumour cells has been analysed |
| Type Of Material | Database/Collection of data |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | Evidence that E-cadherin plays a major part in regulating signalling pathways, proliferation and apoptosis in ES and tumour cells |
| Description | Imagen-biotech |
| Organisation | Imagen Biotech |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of iPS cells derived from Alzheimer's disease patients for use in drug screening applications. |
| Collaborator Contribution | Development of an Alzheimer's disease drug screening platform |
| Impact | Technology still in development |
| Start Year | 2012 |
| Title | CELL CULTURE |
| Description | There is provided a method of retarding differentiation of a biological cell, the method comprising culturing the cell in the presence of an inhibitor of E-cadherin activity. The method is particularly advantageous in retarding the differentiation of stem or progenitor cells, and allows suspension culture of such cells in a manner that enables large scale expansion of cell populations. There is also provided a stem or progenitor cell comprising a construct encoding an inhibitor of E-cadherin activity; and a cell culture medium, for use in the retardation of biological cell differentiation, comprising an inhibitor of E-cadherin activity. |
| IP Reference | WO2007088372 |
| Protection | Patent granted |
| Year Protection Granted | 2007 |
| Licensed | Yes |
| Impact | Further E-cadherin inhibiting peptides have been developed and patented. |
| Title | CELL DIFFERENTIATION |
| Description | Provided is a method of producing neural precursor cells, in which an inhibitor of E-cadherin activity is provided to a population of the cells having neural potential, cell stress is induced among the population of cells; and the surviving cells are cultured until neural precursor cells are produced. Also provided is a method of adapting a cell in vitro for therapeutic use, in which an inhibitor of E-cadherin activity is provided to a population of cells having neural potential, cell stress is induced among the population of cells, and the surviving cells are cultured until neural precursor cells are produced. This method may optionally additionally involve culturing the neural precursor cells until neural cells are produced and formulating the neural precursor cells or neural cells in a composition suitable for administration to a patient. The invention also provides cells produced by these methods. The methods may be practiced on stem cells, particularly iPSCs. The cells and methods have utility in applications including stratified medicine. |
| IP Reference | WO2014072720 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | Yes |
| Impact | Non-exclusive research licence awarded to Imagen-Biotech Ltd |
| Title | Alzheimer's disease diagnostic |
| Description | Alzheimer's disease diagnostic |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2012 |
| Development Status | Actively seeking support |
| Impact | None |
| Company Name | Stratastem |
| Description | Stratastem develops therapeutics for Alzheimer's disease based on neural stem cells, as well as diagnostics for the disease that detect changes in neuronal pathology. |
| Year Established | 2012 |
| Impact | Biotech Start-up |
| Website | http://stratastem.weebly.com |
| Description | Abcam Stem Cell Conference 2009, Antigua. 19th to 22nd of November 2009. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk sparked questions and discussion New collaborations identified |
| Year(s) Of Engagement Activity | 2009 |
| Description | BBSRC Next Generation Conference - commercialisation of research. November 2008. |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussion of commercialisation of research Potential commercial collaborators identified |
| Year(s) Of Engagement Activity | 2008 |
| Description | EPSRC Stem cell strategy development panel. Royal Society, London. Panel member. 16th March 2009 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussion of EPSRC stem cell strategy Final recommendations presented |
| Year(s) Of Engagement Activity | 2009 |
| Description | High throughput screening strategies for neuromuscular disease. TREAT-NMD. Netherlands. 27th Feb - 1st March 2009. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussion of development of tools that industry, clinicians and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice care for neuromuscular patients worldwide. Report produced |
| Year(s) Of Engagement Activity | 2009 |
| Description | Invited lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | MSCA Annual Scientific Meeting, 8th December 2015, Sheffield University, UK. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Invited lecture: Enabling Technologies for Stem Cell and Regenerative Medicine Research. Cambridge 28th November 2012. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk sparked questions and discussion afterwards Industry collaborators identified |
| Year(s) Of Engagement Activity | 2012 |
| Description | Invited lecture: Keystone Symposia A8 2011 Epithelial Plasticity and Epithelial to Mesenchymal Transition, Jan 21 - Jan 26, 2011, Vancouver, British Columbia. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk sparked questions and discussion afterwards. Academic and commercial collaborators identified |
| Year(s) Of Engagement Activity | 2011 |
| Description | Invited lecture: Stem Cells in Drug Discovery conference, 2-3 June 2015, Cambridge University, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Stem Cells in Drug Discovery conference, 2-3 June 2015, Cambridge University, UK |
| Year(s) Of Engagement Activity | 2015 |
| Description | Invited research talk. Uppsala University, Sweden. 13th May 2015. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited research talk. Uppsala University, Sweden. 13th May 2015. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Maths in Medicine Workshop. Keele University 10th-14th Sept 2012 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Mathematical modelling of microarray data achieved. Further collaborations identified |
| Year(s) Of Engagement Activity | 2012 |
| Description | TSB Stratified Medicine strategy on neurodegenerative diseases workshop. October 2013 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussion/workshop on TSB Stratified Medicine strategy on neurodegenerative diseases Recommendations made |
| Year(s) Of Engagement Activity | 2013 |
| Description | The role of BBSRC, TSB and MRC in funding commercial initiatives. BBSRC HQ. Panel member. August 2008 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Workshop discussing the roles of BBSRC, TSB and MRC in funding commercial initiatives. Recommendations made |
| Year(s) Of Engagement Activity | 2008 |